Form 4: Mira Pharmaceuticals CEO Erez Aminov Receives Stock Options
SEC Form 4 Filing
Erez Aminov, CEO of Mira Pharmaceuticals, was granted 379,000 stock options on May 28, 2024, which vested immediately.
Summary
- Erez Aminov, the CEO of Mira Pharmaceuticals, received 379,000 incentive stock options on May 28, 2024.
- These options were granted under the company's 2022 Omnibus Incentive Plan, as amended and restated.
- The exercise price for these options is $0.84, which is equal to the closing price of Mira Pharmaceuticals' common stock on the grant date.
- The options vested immediately upon issuance and expire on May 28, 2034.
- Aminov also holds other stock options granted on April 28, 2023, and August 17, 2023, with varying exercise prices and vesting schedules, bringing his total holdings to 629,000 options.
Sentiment
Score: 6
Explanation: The document is a standard SEC filing related to stock option grants. It's neutral in tone, simply reporting the facts of the transaction. The sentiment is slightly positive as it indicates the CEO is incentivized.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders.
- Immediate vesting of the options may incentivize the CEO to drive short-term performance.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The size and vesting schedule of the grant are typical considerations.
Comparison to Industry Standards
- Stock option grants to CEOs in the pharmaceutical industry vary widely depending on company size, performance, and stage of development.
- Comparing Mira Pharmaceuticals' grant to similar-sized biotech companies would provide a better benchmark.
- For example, CEOs at comparable companies like Galectin Therapeutics or Athersys might receive similar grants as part of their overall compensation packages.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with theirs.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| April 28, 2023 | 50,000 stock options issued to Erez Aminov with an exercise price of $5.00. |
| August 17, 2023 | 150,000 stock options issued to Erez Aminov, vesting immediately, with an exercise price of $6.50 each. |
| August 17, 2023 | 50,000 stock options issued to Erez Aminov, vesting on April 28, 2024, with an exercise price of $6.50 each. |
| May 28, 2024 | Grant date of 379,000 stock options to Erez Aminov at an exercise price of $0.84, vesting immediately and expiring on May 28, 2034. |
| May 30, 2024 | Date of signature for the Form 4 filing. |
| May 28, 2034 | Expiration date of the 379,000 stock options granted on May 28, 2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.